SofWave Medical (SOFW) Stifel 2026 Healthcare Conference 2026 summary

Q3 2026 performance and profitability

• Q3 revenue $28.5M, up 35% YoY; revenue grew at a 42% CAGR from 2021 to 2025, reaching $87.6M in 2025.

• Gross margin exceeded 76%; virtual consumables generated nearly 100% gross margin.

• Utilization revenue was $13.3M, up 60% YoY and 47% of Q3 revenue; capital equipment sales grew 19%.

• Q3 non-IFRS operating income was $4.9M; non-IFRS operating income rose 161% to 17% of revenue, and non-IFRS net income rose 275% YoY to $4.6M.

• Q3 generated $2.6M cash; September-end cash was $41.4M with no debt. Nine-month non-IFRS net income reached 12% of revenue, up 184% YoY.

Business model and installed base

• Sold approximately 3,400 systems across more than 50 countries and surpassed 1.1M treatments; utilization revenue comes from paid pulses used for each treatment.

• U.S. system MSRP is $115,000, while average selling price is under $100,000; clinics can recoup the initial equipment investment in four to six months, with median first-year U.S. clinic ROI of 182%.

• Pulse purchases are mostly by credit card; Q3 DSO was under 30 days. Management expects utilization to grow faster than equipment sales and sees a roughly 50/50 revenue mix, with utilization slightly below 50%, over the next year.

• Management said a 25%–30% long-term EBITDA margin is achievable.

Products, clinical evidence and demand drivers

• Proprietary ultrasound heats the mid-dermis while cooling and protecting the epidermis; treatments are non-invasive, with little downtime and low adverse-event risk.

• The platform has 12 FDA clearances and 14 clinical trials covering more than 600 patients; PureImpact VIP adds muscle stimulation for muscle toning.

• Management sees multi-year aesthetic-market expansion driven by GLP-1 users, menopause and longevity patients, brand awareness, and demand for natural-looking outcomes; the treatment-option market was projected to grow from $63B in 2024 to $97B in 2029 at a 9% CAGR.

• Body applications and the liftHD applicator expand beyond face and neck treatments; larger treatment areas can require more pulses and increase utilization.

• Q3 brand metrics included 58% share of voice, 44% engagement growth, 94% positive sentiment in Q4, and more than 1.6M social followers; marketing leads generated over 40% of equipment sales.